Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Missouri Medicine
|
November 12, 2009
Biologic therapy in Crohn's disease
Michael D Williams, M Louay Omran, Glenn L Gordon
The American Journal of Gastroenterology
|
June 4, 2009
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study
Ellen J Scherl, Ronald Pruitt, Glenn L Gordon, et al.
Digestive Diseases and Sciences
|
November 14, 2015
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission
Gary R Lichtenstein, Glenn L Gordon, Salam Zakko, et al.
Journal of Clinical Gastroenterology
|
September 15, 2015
Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial
Glenn L Gordon, Salam Zakko, Uma Murthy, et al.
Postgraduate Medicine
|
February 11, 2016
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors
Salam F Zakko, Glenn L Gordon, Uma Murthy, et al.
Inflammatory Bowel Diseases
|
May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trial
Remo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Digestive Diseases and Sciences
|
September 21, 2015
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
David T Rubin, William J Sandborn, Brian Bosworth, et al.
Gastroenterology
|
February 4, 2015
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis
William J Sandborn, Brian Bosworth, Salam Zakko, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Missouri Medicine
|
November 12, 2009
Biologic therapy in Crohn's disease
Michael D Williams, M Louay Omran, Glenn L Gordon
The American Journal of Gastroenterology
|
June 4, 2009
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study
Ellen J Scherl, Ronald Pruitt, Glenn L Gordon, et al.
Digestive Diseases and Sciences
|
November 14, 2015
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission
Gary R Lichtenstein, Glenn L Gordon, Salam Zakko, et al.
Journal of Clinical Gastroenterology
|
September 15, 2015
Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial
Glenn L Gordon, Salam Zakko, Uma Murthy, et al.
Postgraduate Medicine
|
February 11, 2016
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors
Salam F Zakko, Glenn L Gordon, Uma Murthy, et al.
Inflammatory Bowel Diseases
|
May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trial
Remo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Digestive Diseases and Sciences
|
September 21, 2015
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
David T Rubin, William J Sandborn, Brian Bosworth, et al.
Gastroenterology
|
February 4, 2015
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis
William J Sandborn, Brian Bosworth, Salam Zakko, et al.
Page
of 1